BG104162A - Pharmaceutical composition active in the reduction of the mcp-1 protein production - Google Patents

Pharmaceutical composition active in the reduction of the mcp-1 protein production

Info

Publication number
BG104162A
BG104162A BG104162A BG10416200A BG104162A BG 104162 A BG104162 A BG 104162A BG 104162 A BG104162 A BG 104162A BG 10416200 A BG10416200 A BG 10416200A BG 104162 A BG104162 A BG 104162A
Authority
BG
Bulgaria
Prior art keywords
mcp
pharmaceutical composition
reduction
composition active
protein production
Prior art date
Application number
BG104162A
Other languages
Bulgarian (bg)
English (en)
Inventor
Angelo Guglielmotti
Claudio Milanese
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Publication of BG104162A publication Critical patent/BG104162A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BG104162A 1997-07-28 2000-02-17 Pharmaceutical composition active in the reduction of the mcp-1 protein production BG104162A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI001788A IT1293794B1 (it) 1997-07-28 1997-07-28 Farmaco attivo nel ridurre la produzione di proteina mcp-1
PCT/EP1998/004925 WO1999004791A1 (en) 1997-07-28 1998-07-22 A pharmaceutical composition active in reducing production of mcp-1 protein

Publications (1)

Publication Number Publication Date
BG104162A true BG104162A (en) 2000-12-29

Family

ID=11377641

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104162A BG104162A (en) 1997-07-28 2000-02-17 Pharmaceutical composition active in the reduction of the mcp-1 protein production

Country Status (15)

Country Link
US (1) US6191158B1 (it)
EP (1) EP0999836A1 (it)
JP (1) JP2001510802A (it)
KR (1) KR20010022333A (it)
CN (1) CN1265592A (it)
AU (1) AU9160298A (it)
BG (1) BG104162A (it)
CA (1) CA2298507A1 (it)
EA (1) EA200000168A1 (it)
HU (1) HUP0004936A3 (it)
IL (1) IL134050A0 (it)
IT (1) IT1293794B1 (it)
SK (1) SK1332000A3 (it)
TR (1) TR200000244T2 (it)
WO (1) WO1999004791A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970194A (en) * 1975-01-08 1976-07-20 Philip Morris Incorporated Razor blade cartridge and display article
IT1147079B (it) * 1980-05-30 1986-11-19 Sigma Tau Ind Farmacuetiche Ri Esteri di alcossi-acil derivati della carnitina procedimento per la loro preparatione e composizioni farmaceutiche che li contengono
IT1131779B (it) * 1980-07-29 1986-06-25 Acraf Sale dell'acido (1-benzil-1h-indazol-3-il)-ossiacetico con la lisina e procedimento per la sua preparazione
IT1189052B (it) * 1981-11-27 1988-01-28 Acraf Trattamento della cataratta
IT1197805B (it) * 1986-08-01 1988-12-06 Acraf Metodo per il tratamento di lenti a contatto

Also Published As

Publication number Publication date
HUP0004936A3 (en) 2002-01-28
TR200000244T2 (tr) 2000-09-21
KR20010022333A (ko) 2001-03-15
EP0999836A1 (en) 2000-05-17
IL134050A0 (en) 2001-04-30
ITMI971788A1 (it) 1999-01-28
IT1293794B1 (it) 1999-03-10
HUP0004936A2 (hu) 2001-11-28
SK1332000A3 (en) 2000-12-11
AU9160298A (en) 1999-02-16
EA200000168A1 (ru) 2000-08-28
CN1265592A (zh) 2000-09-06
WO1999004791A1 (en) 1999-02-04
JP2001510802A (ja) 2001-08-07
US6191158B1 (en) 2001-02-20
CA2298507A1 (en) 1999-02-04

Similar Documents

Publication Publication Date Title
MY115662A (en) Novel compounds with analgesic effect
WO2000046199A3 (en) Indole derivatives as anti-inflammation agents
AP2002002637A0 (en) Novel piperazine
JO3404B1 (ar) تركيبة صيدلانية سائلة تحتوي على مشتقات اريثروبويتين
MY130145A (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders.
ZA992951B (en) N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders.
CA2274074A1 (en) Novel compounds with analgesic effect
NZ514711A (en) Compounds useful as anti-inflammatory agents
BG106586A (en) Pyrazolopyramidines as therapeutic agents
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
MY132705A (en) Novel compounds with analgesic effect
CA2289717A1 (en) Novel therapy for constipation
MY113733A (en) Salts of an anti-migraine indole derivative
CA2129995A1 (en) Piperidinyl thiacyclic derivatives
GEP20022654B (en) Indazole Amide Compounds As Serotoninergic Agents
GEP20053617B (en) Bridged Piperazine Derivatives
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
MY113062A (en) Amide derivatives and their therapeutic use
WO1999004770A3 (en) A pharmaceutical composition active in reducing production of mcp-1 protein
HUP0300863A2 (hu) N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény
GEP19991869B (en) Amino Acid Derivatives of Substituted Quinoxaline 2,3-Dione Derivatives as Glutamate Receptor Antagonists